Clinical Evaluation of Jawārish-i-Kamūnī and ‘Arq-i-Bādiyān in Sū’ al-Haḍm (Dyspepsia)

Abstract Background: Sū’ al-Haḍm (Dyspepsia) is one of the most common ailments in nowadays sedentary lifestyle. The are many efficacious medicines for the treatment of Dyspepsia in the Unani system of medicine, and Jawārish-i-Kamūnī and ‘Arq-i-Bādiyān are among them. Objective: The study is planned to evaluate the safety and efficacy of Unani pharmacopeial formulations Jawārish-i-Kamūnī and ‘Arq-i-Bādiyān in patients of Sū’ al-Haḍm (Dyspepsia). Materials and Methods: This Sū’ al-Haḍm (Dyspepsia) study was a single-arm, open-label, with 60 clinically diagnosed cases of Dyspepsia belonging to 18–55 years of age, either sex, who had agreed to sign the informed consent form and follow the protocol. The patients were treated with Unani formulations, i.e., 5 g of Jawārish-i-Kamūnī orally twice and 60 ml ‘Arq-i-Bādiyān orally twice with water after meals for 2 weeks with two follow-ups. The assessments of subjective and objective parameters were done every week and recorded in a case record form. The results were recorded in terms of the percentage of efficacy calculated from the gastrointestinal symptom rating scale analyzed statistically. Results: The subjective parameters like abdominal pain, heartburn, acid regurgitation, eructation, nausea and vomiting, and abdominal distention were significantly improved by 59.85%, 57.23%, 61.14%, 62.87%, 52.38%, and 79.70%, respectively, as compared to baseline with P < 0.0001. No significant adverse changes were observed in safety parameters during and after the trial. Conclusion: It can be concluded that the Unani formulations Jawārish-i-Kamūnī and ‘Arq-i-Bādiyān are safe and effective in Dyspepsia treatment.